MUC1 decoy peptides for treatment and prevention of bacterial infections
AssigneeUniversity of Maryland, Baltimore
InventorsErik P. Lillehoj, Avelino C. Verceles, Simeon E. Goldblum
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Maryland, Baltimore
InventorsErik P. Lillehoj, Avelino C. Verceles, Simeon E. Goldblum
Estimating the term…
Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection. Such findings are extended to the methods of treatment and prevention of bacterial infections defined herein.
A method of treating or preventing a pulmonary infection caused by Pseudomonas aeruginosa in a subject, comprising administering to the subject a therapeutically effective amount of an ectodomain MUC1 decoy peptide comprising the amino acid sequence set forth in SEQ ID NO:3.
Dependencies are inferred from the claim text.